Compare BIO-TECHNE Corp (TECH) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wendys Co — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while Wendys Co trades at $6.12 (market cap $1.19B). The key difference: BIO-TECHNE Corp is far larger — about 9.5× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Wendys Co for 77 Days on average.
| TECH | WEN | |
|---|---|---|
Market Cap | $11.36B | $1.19B |
Volume | 5,390,331 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $72.61 | $9.33 |
52-Week Low | $43.31 | $6.10 |
Typical Hold Time | 63 Days | 77 Days |
Enterprise Value | $11.39B | $4.92B |
Dividend Yield | 0.44% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Wendy's stock (WEN) trades at $6.11, down 0.81% on the day, reflecting ongoing pressure from declining sales and a major franchisee bankruptcy. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a low P/E of 9.45 and strong ROE of 108.04%, but net income margins have fallen to 5.72%. Recent news highlights competitive struggles and store closures, though the company continues to beat earnings expectations.
The outlook remains cautious due to operational headwinds and high debt, but the current valuation may appeal to value investors. Risks include franchisee instability and intense competition. Analyst consensus is mixed with a $7.58 price target, suggesting limited upside from current levels amid uncertain recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
